Arcus Biosciences, Inc.

Other

Jenna Leigh Jeffrey

Manmohan Reddy Leleti

Jay Patrick Powers

Joel Worley Beatty

Kenneth Victor Lawson

Debashis Mandal

Xuelei Yan

Brandon Reid Rosen

Dillon Harding Miles

Rhiannon Thomas-Tran

Samuel Lawrie Drew

Guillaume Mata

Jaroslaw Kalisiak

Erick Allen Lindsey

Artur Karenovich Mailyan

Anh Thu Tran

Steven Donald Jacob

Zhang Wang

Jeremy Thomas Andre Fournier

Hyunyoung Moon

Ehesan Ul Sharif

Yongli Su

Balint Gal

Matthew Epplin

Tezcan Guney

Clayton Hardman

Kai Yu

Karl T Haelsig

Laurent Debien

Juan Carlos Jaen

Laurent Pierre Paul Debien

Ehesan Ui Sharif

Rebecca Louise Grange

Jeremy Fournier

Joyson J Karakunnel

Srinivas Paladugu

Lixia Jin

Karen Yir Jing Chen

Pradeep Nareddy

Monika Yadav

Manjunath Lamani

Srijita Bhowmik

Jiang Zhu

Methods of identifying compounds that modulate the conversion of AMP to adenosine by 5'-nucleotidase, ecto, and that possess particular pharmacokinetic characteristics are described herein. Methods of such compounds, and compositions comprising same, for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, are also provided.

Parenterally administered immune enhancing drugs

Compounds that inhibit PI3Kγ, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by PI3Kγ.

2,3,5-trisubstituted pyrazolo[1,5-A]pyrimidine compounds

The present disclosure is directed to compounds having a structure according to Formula I, and compositions containing those compounds. Methods of using the compounds for the treatment of diseases, disorders, or conditions are also described.

Thiazole compounds and methods of use thereof

Compound that is an inhibitor of at least one of the Aand Aadenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. The use of such compound and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine Areceptor and/or the adenosine Areceptor.

Azolopyrimidine for the treatment of cancer-related disorders

Compounds that inhibit HIF-2α, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2α.

Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha

The present invention provides solid forms, solvates and hydrates of 3-[2-amino-6-(1-{[6-(2-hydroxypropan-2-yl)pyridin-2-yl]methyl}-1H-1,2,3-triazol-4-yl)pyrimidin-4-yl]-2-methylbenzonitrile (Compound I),

Solid forms of an azolopyrimidine compound

Compounds, such as compounds having Formula (I): wherein each variable is as described herein, that modulate the conversion of AMP to adenosine by 5′-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5′-nucleotidase, ecto is also provided.

CD73 inhibitors

Solid forms of Compound I, which modulates the conversion of AMP to adenosine by 5'-nucleotidase, ecto, and compositions containing the compound and methods for preparing the solid forms, are described herein. The use of such solid form of Compound I and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5&#x2032;-nucleotidase, ecto is also provided.

Solid forms of a CD73 inhibitor and the use thereof

Compounds that inhibit HIF-2&#x3b1;, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2&#x3b1;.

Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2&#x3b1;

Growing community of inventors

Oakland, CA, United States of America

Jenna Leigh Jeffrey